RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Pick your excuse for the failed bounce today, but chatter out of the Centers for Disease Control and Prevention works for us.
Speaking at a press briefing, the CDC’s Jay Butler says “mitigation efforts” similar to March, i.e. economic shutdown, may be necessary should cases “dramatically” rise.
At the moment there are a number of report of rising cases in reopened areas – by itself not too much of an issue if the rise correlates to a rise in testing (though a Morgan Stanley report yesterday suggests otherwise). But there are also reports of rising hospitalizations – again, by itself not a huge issue if that correlates to folks headed back to hospitals for elective surgeries.
Up nearly 2% earlier, the S&P 500 had turned red not long ago. It’s since bounced a bit, now ahead 0.4% for the day.
Unsurprisingly, AbbVie (NYSE:ABBV) is urging stockholders to reject a mini-tender offer from TRC Capital for 1.5M common shares at $88.05, ~5% below today’s $92.46 close.
Shares up a fraction after hours.
Sorrento Therapeutics (SRNE -3.5%) announces that it has paid off its outstanding term loans totaling $120M.
On April 27, it filed a prospectus supplement for a $250M public offering of common stock.
Preliminary data show mice receiving one dose of Moderna’s (NASDAQ:MRNA) COVID-19 vaccine were sufficiently protected against the virus, without increasing the risk of more severe disease.
Shares are up 1.7% on the session.
The FDA approves ViiV Healthcare’s Tivicay (dolutegravir) for the treatment of HIV-1 infection in children as young as four weeks old and weighing at least 3 kg, in combination with other antiretroviral treatments.
The agency approved the HIV-1 integrase strand transfer inhibitor in August 2013 for HIV-1-positive patients at least 12 years old and weighing at least 40 kg.
ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK -0.3%), Pfizer (PFE +0.3%) and Shionogi (OTCPK:SGIOY +1.3%).
